Home >> Signaling Pathways >> JAK/STAT Signaling

JAK/STAT Signaling

Targets for  JAK/STAT Signaling

Products for  JAK/STAT Signaling

  1. Cat.No. Product Name Information
  2. GC38006 β-Hydroxyisovalerylshikonin Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC50s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells. β-Hydroxyisovalerylshikonin  Chemical Structure
  3. GC34964 (1S,3R,5R)-PIM447 dihydrochloride

    (1S,3R,5R)-LGH447 dihydrochloride

    (1S,3R,5R)-PIM447 (dihydrochloride) an PIM inhibitor extracted from patent US 20100056576 A1, compound example 72, has IC50 values of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3. (1S,3R,5R)-PIM447 dihydrochloride  Chemical Structure
  4. GC34971 (3R,4S)-Tofacitinib (3R,4S)-Tofacitinib is an less active enantiomer of Tofacitinib. (3R,4S)-Tofacitinib  Chemical Structure
  5. GC34972 (3S,4R)-Tofacitinib (3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. (3S,4R)-Tofacitinib  Chemical Structure
  6. GC34973 (3S,4S)-Tofacitinib (3S,4S)-Tofacitinib is the less active S-enantiomer of Tofacitinib. (3S,4S)-Tofacitinib  Chemical Structure
  7. GC61807 (E/Z)-AG490 (E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3. (E/Z)-AG490  Chemical Structure
  8. GC63864 (E/Z)-Zotiraciclib hydrochloride

    (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride

    (E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, JAK2, and FLT3 inhibitor. (E/Z)-Zotiraciclib hydrochloride  Chemical Structure
  9. GC69836 (R,R)-VVD-118313

    (R,R)-VVD-118313 is an isomer of VVD-118313. VVD-118313 is a selective JAK1 inhibitor that can block JAK1-dependent phosphorylation and cytokine signaling. VVD-118313 can be used for cancer research.

    (R,R)-VVD-118313  Chemical Structure
  10. GC63797 (S)-Sunvozertinib

    (S)-DZD9008

    (S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK. (S)-Sunvozertinib  Chemical Structure
  11. GC46503 2-(1,8-Naphthyridin-2-yl)phenol

    2-NP

    2-(1,8-Naphthyridin-2-yl)phenol is a selective enhancer of STAT1 transcription. 2-(1,8-Naphthyridin-2-yl)phenol can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells. 2-(1,8-Naphthyridin-2-yl)phenol  Chemical Structure
  12. GC12138 5,15-DPP

    5,15-Diphenylporphyrin,STAT3 Inhibitor VIII

    5,15-DPP (5,15-DPP) is a selective STAT3-SH2 antagonist (IC50s of 0.28 μM and 10 μM for STAT3 and STAT1, respectively). 5,15-DPP  Chemical Structure
  13. GC32023 Abrocitinib (PF-04965842)

    PF-04965842

    Abrocitinib (PF-04965842) (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842)  Chemical Structure
  14. GC62272 AC-4-130 AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML). AC-4-130  Chemical Structure
  15. GC13257 AC480 (BMS-599626)

    BMS-599626

    AC480 (BMS-599626) (AC480) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. AC480 (BMS-599626) displays ~8-fold less potent to HER4 (IC50=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. AC480 (BMS-599626) inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy. AC480 (BMS-599626)  Chemical Structure
  16. GC11892 AEE788 (NVP-AEE788)

    NVP-AEE788

    AEE788 (NVP-AEE788) is an inhibitor of the EGFR and ErbB2 with IC50 values of 2 and 6 nM, respectively. AEE788 (NVP-AEE788)  Chemical Structure
  17. GC11744 AG 555

    Tyrphostin AG-555, Tyrphostin B46

    Potent EGFR-kinase inhibitor AG 555  Chemical Structure
  18. GC13168 AG 825

    Tyrphostin AG825

    Selective ErbB2 inhibitor AG 825  Chemical Structure
  19. GC14494 AG 99

    Tyrphostin 46, Tyrphostin AG-99

    AG 99 ((E)-Tyrphostin 46) is a potent EGFR inhibitor. AG 99  Chemical Structure
  20. GC17226 AG-1478

    Tyrphostin AG-1478; AG 1478; NSC 693255; AG1478

    EGFR inhibitor,potent and selective AG-1478  Chemical Structure
  21. GC12864 AG-1557

    Tyrphostin AG-1557

    inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase AG-1557  Chemical Structure
  22. GC17647 AG-18

    RG50810, RG50858, TX 825, Tyrphostin 23, Tyrphostin AG18

    AG-18 (Tyrphostin A23) is an EGFR inhibitor with an IC50 and Kiof 35 and 11 μM, respectively. AG-18  Chemical Structure
  23. GC13854 AG-490 (Tyrphostin B42)

    Tyrphostin AG-490

    AG-490 (Tyrphostin B42) (Tyrphostin AG-490 (Tyrphostin B42)) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3. AG-490 (Tyrphostin B42)  Chemical Structure
  24. GN10705 Alantolactone

    (+)-Alantolactone, NSC 333843, NSC 93131

    Alantolactone  Chemical Structure
  25. GC64398 Almonertinib mesylate

    HS-10296 mesylate

    Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer. Almonertinib mesylate  Chemical Structure
  26. GC67749 Amivantamab

    JNJ-61186372

    Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity

    Amivantamab  Chemical Structure
  27. GC60585 Angoline Angoline is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation. Angoline  Chemical Structure
  28. GC60586 Angoline hydrochloride Angoline hydrochloride is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline hydrochloride inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation. Angoline hydrochloride  Chemical Structure
  29. GC17283 AP26113

    Brigatinib

    AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1. AP26113  Chemical Structure
  30. GC10439 APTSTAT3-9R STAT3 inhibitor APTSTAT3-9R  Chemical Structure
  31. GC35395 Arnicolide D

    ARD

    Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the caspase signaling pathway and inhibits the PI3K/AKT/mTOR and STAT3 signaling pathways. Arnicolide D inhibits Nasopharyngeal carcinoma (NPC) cell viability in a concentration- and time-dependent manner. Arnicolide D  Chemical Structure
  32. GC12478 ARRY-380

    ARRY380; ARRY 380

    ARRY-380, an inhibitor of EGFR (ErbB1), is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2. ARRY-380  Chemical Structure
  33. GC10889 Artesunate

    Artesunic Acid, NSC 712571, WR 256283

    Derivative of the natural product artemisinin Artesunate  Chemical Structure
  34. GC19039 AS1517499 A potent STAT6 inhibitor AS1517499  Chemical Structure
  35. GC61574 AS1810722 AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722  Chemical Structure
  36. GC38736 AS2863619 A dual inhibitor of Cdk8 and Cdk19 AS2863619  Chemical Structure
  37. GC38737 AS2863619 free base AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 free base  Chemical Structure
  38. GC40715 Ascochlorin

    Antibiotic LL-Z1272γ, Ilicicolin D, NSC 287492

    Ascochlorin is an isoprenoid antibiotic and antiviral that has diverse effects on mammalian cells. Ascochlorin  Chemical Structure
  39. GC11691 AST-1306

    AST1306; AST 1306

    AST-1306 (AST-1306) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 is an anilino-quinazoline compound and has anti-cancer activity. AST-1306  Chemical Structure
  40. GC15669 AST-1306 TsOH

    Allitinib

    AST-1306 TsOH (AST-1306 (TsOH)) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 TsOH also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 TsOH is an anilino-quinazoline compound and has anti-cancer activity AST-1306 TsOH  Chemical Structure
  41. GC33096 AST2818 mesylate

    AST2818

    Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of EGFR. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib (Furmonertinib) mesylate has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC). AST2818 mesylate  Chemical Structure
  42. GC35413 Astragaloside VI Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing. Astragaloside VI  Chemical Structure
  43. GN10627 Atractylenolide I Atractylenolide I  Chemical Structure
  44. GC35435 AV-412

    MP-412

    A dual inhibitor of EGFR and HER2 AV-412  Chemical Structure
  45. GC35436 AV-412 free base

    MP-412 free base

    AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively. AV-412 free base  Chemical Structure
  46. GC19044 Avitinib maleate

    A pyrrolopyrimidine-based irreversible EGFR inhibitor

    Avitinib maleate  Chemical Structure
  47. GC12955 AZ5104 EGFR inhibitor AZ5104  Chemical Structure
  48. GC16308 AZD-9291

    osimertinib

    AZD-9291 (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. AZD-9291 overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. AZD-9291  Chemical Structure
  49. GC16698 AZD-9291 mesylate AZD-9291 mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. AZD-9291 mesylate  Chemical Structure
  50. GC35447 AZD1208 hydrochloride AZD1208 hydrochloride is an orally bioavailable, highly selective PIM kinases inhibitor. AZD1208 hydrochloride  Chemical Structure
  51. GC13143 AZD3759

    AZD3759

    AZD3759 (AZD3759) is a potent, orally active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFRwt, EGFRL858R, and EGFRexon 19Del, respectively. AZD3759  Chemical Structure
  52. GC13761 AZD8931 (Sapitinib)

    Sapitinib

    AZD8931 (Sapitinib) (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC50s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively. AZD8931 (Sapitinib)  Chemical Structure
  53. GC18126 Balsalazide anti-inflammatory drug Balsalazide  Chemical Structure
  54. GC35466 Balsalazide sodium hydrate Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. Balsalazide sodium hydrate  Chemical Structure
  55. GC64302 BAY 2476568 BAY 2476568 is a potent and selective EGFR inhibitor, with IC50s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG). BAY 2476568  Chemical Structure
  56. GC64017 Befotertinib

    D-0316

    Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC). Befotertinib  Chemical Structure
  57. GC33172 BGB-102 (JNJ-26483327) BGB-102 (JNJ-26483327) is a potent multi-kinase inhibitor against EGFR, HER2, and HER4 with IC50s of 9.6 nM, 18 nM and 40.3 nM, respectively. BGB-102 (JNJ-26483327)  Chemical Structure
  58. GC19066 BGB-283 BGB-283 is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively. BGB-283  Chemical Structure
  59. GC68759 BI-1622

    BI-1622 is an orally effective and highly selective HER2 (ERBB2) inhibitor with an IC50 of 7 nM. BI-1622 has a selectivity for EGFR greater than 25-fold. In transplant mouse models of H2170 and PC9 cells, BI-1622 showed high in vivo anti-tumor effects and has good activity molecular metabolism and pharmacokinetic properties.

    BI-1622  Chemical Structure
  60. GC38402 BI-4020 A fourth-generation and non-covalent EGFR tyrosine kinase inhibitor BI-4020  Chemical Structure
  61. GC68762 BI-4142

    BI-4142 is an effective, highly selective, orally active HER2 inhibitor with an IC50 value of 5 nM.

    BI-4142  Chemical Structure
  62. GC63910 BLU-945 BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC). BLU-945  Chemical Structure
  63. GC32028 BMS-066 BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor, with IC50s of 9 nM and 72 nM, respectively. BMS-066  Chemical Structure
  64. GC34063 BP-1-102 A STAT3 inhibitor BP-1-102  Chemical Structure
  65. GC42974 Brassinin

    BSN

    Brassinin (BSN) is a phytoalexin isolated from B. Brassinin  Chemical Structure
  66. GC25168 Brepocitinib (PF-06700841)

    PF-841

    Brepocitinib (PF-06700841, PF-841) is a potent inhibitor of Tyk2 and Jak1 with IC50s of 23 nM, 17 nM, 77 nM for Tyk2, Jak1 and Jak2 respectively. It has appropriate in-family selectivity against JAK2 and JAK3. Brepocitinib (PF-06700841)  Chemical Structure
  67. GC35554 Brevilin A

    6-O-Angeloylprenolin, Brevelin A

    A sesquiterpene lactone with anticancer activity Brevilin A  Chemical Structure
  68. GC10944 Butein

    2’,3,4,4’tetrahydroxy Chalcone

    Protein kinase inhibitor Butein  Chemical Structure
  69. GC68819 Butyzamide

    Butyzamide is an orally effective Mpl activator, where Mpl is a receptor for thrombopoietin (TPO) involved in platelet production. Butyzamide increases the phosphorylation levels of JAK2, STAT3, STAT5 and MAPK. In mouse xenograft experiments, Butyzamide increases human platelet levels.

    Butyzamide  Chemical Structure
  70. GC34076 C188-9

    TTI-101

    A STAT3 inhibitor C188-9  Chemical Structure
  71. GC12910 Canertinib (CI-1033) Canertinib (CI-1033) (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib (CI-1033)  Chemical Structure
  72. GC47061 CAY10763 A dual inhibitor of IDO1 and STAT3 activation CAY10763  Chemical Structure
  73. GC49139 CAY10784 A STAT3 inhibitor CAY10784  Chemical Structure
  74. GC35651 Cenisertib

    AS-703569; R-763

    Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia. Cenisertib  Chemical Structure
  75. GC11209 Cerdulatinib (PRT062070)

    PRT062070, PRT2070

    Cerdulatinib (PRT062070) (PRT062070) is a selective Tyk2 inhibitor with an IC50 of 0.5 nM. Cerdulatinib (PRT062070) (PRT062070) also is a dual JAK and SYK inhibitor with IC50s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively. Cerdulatinib (PRT062070)  Chemical Structure
  76. GC34217 Cetuximab (C225)

    C225

    Cetuximab (C225) (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab (C225) has potent antitumor activity. Cetuximab (C225)  Chemical Structure
  77. GC15950 CGP 52411

    CGP 52411, 4,5-Dianilinophthalimide

    EGFR inhibitor CGP 52411  Chemical Structure
  78. GC25219 CH7233163 CH7233163 is a non-covalent ATP competitive inhibitor of EGFR-tyrosine kinase with antitumor activities against tumor with EGFR-Del19/T790M/C797S. CH7233163  Chemical Structure
  79. GC35684 CHMFL-EGFR-202 CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ?10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines. CHMFL-EGFR-202  Chemical Structure
  80. GC11652 CHZ868 Type II JAK2 inhibitor CHZ868  Chemical Structure
  81. GC17790 CL-387785 (EKI-785)

    EKB-785, EKI-785, WAY-EKI-785

    CL-387785 (EKI-785)(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370 pM. CL-387785 (EKI-785)  Chemical Structure
  82. GC34238 CMD178 CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development. CMD178  Chemical Structure
  83. GC35715 CMD178 TFA CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development. CMD178 TFA  Chemical Structure
  84. GC11264 CNX-2006

    mutant-EGFR inhibitor, selective and irreversible

    CNX-2006  Chemical Structure
  85. GC14854 Colivelin Colivelin (CLN) is A brain-permeable neuroprotective peptide that has effective long-term effects on Aβ deposition, neuronal apoptosis and synaptic plasticity defects in neurodegenerative diseases. Colivelin  Chemical Structure
  86. GC35720 Colivelin TFA Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3?in vitro. Colivelin TFA  Chemical Structure
  87. GC13279 Corylifol A

    Corylinin

    STAT3 inhibitor Corylifol A  Chemical Structure
  88. GC13091 CP-724714 HER2 inhibitor,potent and selective CP-724714  Chemical Structure
  89. GN10501 Cryptotanshinone Cryptotanshinone  Chemical Structure
  90. GC13347 Cucurbitacin I

    Elatericin B; JSI-124; NSC-521777

    An inhibitor STAT3/JAK signaling Cucurbitacin I  Chemical Structure
  91. GN10442 Curculigoside Curculigoside  Chemical Structure
  92. GC35762 CX-6258 hydrochloride hydrate CX-6258 hydrochloride hydrate is a potent and kinase selective pan-Pim kinases inhibitor, with IC50s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively. CX-6258 hydrochloride hydrate  Chemical Structure
  93. GC38180 Cyasterone Cyasterone  Chemical Structure
  94. GC10225 Dacomitinib (PF299804, PF299)

    PF-00299804; PF-299804; PF 299804; PF 00299804

    Dacomitinib (PF299804, PF299) (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively. Dacomitinib (PF299804, PF299)  Chemical Structure
  95. GC65020 Danvatirsen

    AZD9150

    Danvatirsen is an antisense oligonucleotide targeting STAT3 with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth. Danvatirsen  Chemical Structure
  96. GC31660 Delgocitinib (JTE-052) Delgocitinib (JTE-052) (JTE-052) is a specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. Delgocitinib (JTE-052)  Chemical Structure
  97. GC43406 Delphinidin (chloride)

    Ephdine

    Delphinidin (chloride) is an anthocyanidin, a natural plant pigment which serves as the precursor of certain anthocyanins that provide the blue-red colors of flowers, fruits, and red wine.

    Delphinidin (chloride)  Chemical Structure
  98. GC34101 Dihydroisotanshinone I Dihydroisotanshinone I  Chemical Structure
  99. GN10115 Diosgenin

    Nitogenin, NSC 33396, 3β-hydroxy-5-Spirostene

    Diosgenin  Chemical Structure
  100. GC68986 Disitamab

    RC48-0

    Disitamab (RC48-0) is a humanized monoclonal antibody that targets HER2. Disitamab can be used to synthesize antibody-drug conjugates (ADCs), such as Disitamab vedotin.

    Disitamab  Chemical Structure
  101. GC64039 Disitamab vedotin Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity. Disitamab vedotin  Chemical Structure

Items 1 to 100 of 349 total

per page
  1. 1
  2. 2
  3. 3
  4. 4

Set Descending Direction